Skip to main content
. 2018 Feb 15;152:76–83. doi: 10.1016/j.antiviral.2018.02.009

Fig. 5.

Fig. 5

The growth kinetics (A) and susceptibility (B) of FCV mutants to fexaramine or NPI52. An infectious recombinant FCV full-genome clone carrying A539T in the VP1 gene or T138S in the 3CLpro gene was generated using the reverse genetics system of FCV. A. The growth kinetics of WT- and the mutant FCVs were compared. WT, M Cap A539T and M Pro T138S indicate WT, mutant FCV carrying A539T in the VP1 and recombinant FCV carrying T138S in the 3CLpro, respectively. B. The fold changes in the EC50 values of fexaramine or NPI52 against each mutant FCV compared to WT FCV were determined in cell culture.